IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i6d10.1007_s40264-021-01067-x.html
   My bibliography  Save this article

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan

Author

Listed:
  • Kunihiro Yamaoka

    (Kitasato University School of Medicine)

  • Yoshiya Tanaka

    (University of Occupational and Environmental Health)

  • Hideto Kameda

    (Toho University (Ohashi Medical Center))

  • Nasser Khan

    (AbbVie Inc.)

  • Nobuhito Sasaki

    (AbbVie GK)

  • Masayoshi Harigai

    (Tokyo Women’s Medical University School of Medicine)

  • Yanna Song

    (AbbVie Inc.)

  • Ying Zhang

    (AbbVie Inc.)

  • Tsutomu Takeuchi

    (Keio University School of Medicine)

Abstract

Introduction Upadacitinib is a Janus kinase inhibitor with demonstrated efficacy in patients with rheumatoid arthritis (RA). Objective The aim of this study was to assess the long-term safety of upadacitinib in patients with active RA from Japan compared with global clinical trial populations. Methods Pooled data in patients enrolled from Japan (the ‘Japanese population’; SELECT-SUNRISE, SELECT-EARLY, and SELECT-MONOTHERAPY) were compared with that from global (Japan and ex-Japan) upadacitinib clinical trial populations and summarized descriptively. Results The Japanese population (mean age 57.0 years; mean RA duration 6.1 years) received upadacitinib 7.5 mg (n = 121), 15 mg (n = 126), and 30 mg (n = 124) once daily, while the global population (mean age 54.8 years; mean RA duration 9.1 years) received upadacitinib 6 mg twice daily/15 mg once daily (n = 2883) and 12 mg twice daily/30 mg once daily (n = 1375). Most patients were female (79.3%). The exposure-adjusted incidence rates (EAIRs) of serious adverse events in the Japanese population were 11.5, 12.2, and 21.2 per 100 patient-years (PY) with upadacitinib 7.5, 15, and 30 mg, respectively. Herpes zoster rates were higher in the Japanese population (7.8, 12.4, and 16.7 per 100 PY with 7.5, 15, and 30 mg, respectively) versus global populations (3.7 and 7.0 per 100 PY with 15 and 30 mg, respectively). Prior herpes zoster was a significant risk factor for herpes zoster. Conclusions The safety profile of upadacitinib was generally similar between Japanese and global RA populations, except for higher EAIRs for serious adverse events and infections, including herpes zoster, in the Japanese population. Trial Registration Numbers SELECT-EARLY: NCT02706873; SELECT-NEXT: NCT02675426; SELECT-COMPARE: NCT02629159; SELECT-MONOTHERAPY: NCT02706951; SELECT-BEYOND: NCT02706847; SELECT-SUNRISE: NCT02720523; BALANCE I: NCT01960855; BALANCE II: NCT02066389.

Suggested Citation

  • Kunihiro Yamaoka & Yoshiya Tanaka & Hideto Kameda & Nasser Khan & Nobuhito Sasaki & Masayoshi Harigai & Yanna Song & Ying Zhang & Tsutomu Takeuchi, 2021. "The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan," Drug Safety, Springer, vol. 44(6), pages 711-722, June.
    • Handle: RePEc:spr:drugsa:v:44:y:2021:i:6:d:10.1007_s40264-021-01067-x
    DOI: 10.1007/s40264-021-01067-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-021-01067-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-021-01067-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Philip G. Conaghan & Eduardo Mysler & Yoshiya Tanaka & Barbara Silva-Tillmann & Tim Shaw & John Liu & Ryan Ferguson & Jeffrey V. Enejosa & Stanley Cohen & Peter Nash & William Rigby & Gerd Burmester, 2021. "Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program," Drug Safety, Springer, vol. 44(5), pages 515-530, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:6:d:10.1007_s40264-021-01067-x. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.